Immorna Biotherapeutics Gets U.S. FDA IND Approval for JCXH-211 IV Phase 1/2 Trial Alone and with Checkpoint Inhibitor in Advanced Solid Tumor Patients.

Mirum Pharmaceuticals, Inc. revealed that the European Commission has approved the marketing authorization for LIVMARLI® (maralixibat) oral solution

Regeneron Pharmaceuticals, Inc. and Sanofi announced today that the European Commission has granted approval for Dupixent (dupilumab) as an additional maintenance therapy for adults with uncontrolled chronic obstructive pulmonary disease with elevated blood eosinophils.

Cartesian Therapeutics, revealed that the initial patient has been treated in its Phase 2 open-label clinical study assessing Descartes-08 in individuals with systemic lupus erythematosus.

Checkpoint Therapeutics has announced the successful resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for cosibelimab.

BioCity reveals SC0062, an endothelin receptor A selective antagonist, has achieved its main objective in a Phase 2 study (2-SUCCEED) for IgA nephropathy. The trial was randomized, double-blind, and placebo-controlled.

Epsilogen reveals CTA green light for Phase Ib study of MOv18 IgE in platinum-refractory ovarian cancer.

CSL Behring Treats First Hemophilia B Patients in Europe with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy.

Johnson & Johnson revealed that the U.S. Food and Drug Administration has granted conventional approval for SIRTURO (bedaquiline).

Sobi submits biologics license application to the FDA for SEL-212, targeting chronic refractory gout treatment.

Tyra Biosciences has reported preclinical proof-of-concept findings for TYRA-300, an experimental orally administered FGFR3 selective inhibitor.

Satellos Reveals Initial Data Indicating Muscle Recovery and Healing from SAT-3247 Treatment in Dog Model of Duchenne Muscular Dystrophy (DMD).